» Articles » PMID: 33733487

Microglia-derived Galectin-3 in Neuroinflammation; a Bittersweet Ligand?

Overview
Journal Med Res Rev
Publisher Wiley
Date 2021 Mar 18
PMID 33733487
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Galectins are soluble β-galactoside-binding proteins found in all multicellular organisms. Galectins may act as danger-associated molecular patterns in innate immunity and/or as pattern-recognition receptors that bind to pathogen-associated molecular patterns. Among different galectin family members, galectin-3 has been the focus of studies in neurodegenerative diseases in recent years. This lectin modulates brain innate immune responses, microglia activation patterns in physiological and pathophysiological settings in a context-dependent manner. Galectin-3 is considered as a pivotal tuner of macrophage and microglial activity. Indeed galectin-3 acts as a double edged sword in neuroinflammatory context and this multimodal lectin has diverse roles in physiological and pathophysiological conditions. Better understanding of galectin-3 physiology (its extracellular and intracellular actions) and structure (its C terminus vs. N terminus) is instrumental to design molecules that selectively modulate galectin-3 function toward neuroprotective phenotypes. Several experimental studies using different approaches and methods have demonstrated both protective and deleterious effects of galectin-3 in neuroinflammatory diseases. According to the crucial role of galectin-3 in modulation of innate immune response in brain, it is an attractive target in drug discovery of neurodegenerative diseases. The current insight attempts to provide an updated and balanced discussion on the role of galectin-3 as a complex endogenous immune modulator. This helps to have a better insight into the development of galectin-3 modulators with translational value in different neurological disorders including stroke and neurodegenerative diseases, such as Alzheimer's disease, Huntington's disease and Parkinson's disease.

Citing Articles

Transcriptomic Analysis Divulges Differential Expressions of Microglial Genes After Microglial Repopulation in Mice.

Hafeez M, Gao H, Ju F, Qi F, Li T, Zhang S Int J Mol Sci. 2025; 26(4).

PMID: 40003960 PMC: 11855859. DOI: 10.3390/ijms26041494.


Development and validation of Galectin-3 and CVAI-based model for predicting cognitive impairment in type 2 diabetes.

Zhou X, Dai N, Yu D, Niu T, Wang S J Endocrinol Invest. 2024; .

PMID: 39565520 DOI: 10.1007/s40618-024-02506-z.


The double-edged role and therapeutic potential of TREM2 in atherosclerosis.

Zhu B, Liu Y, Peng D Biomark Res. 2024; 12(1):131.

PMID: 39497214 PMC: 11533605. DOI: 10.1186/s40364-024-00675-w.


Exploring galectin-3's role in predicting mild cognitive impairment in type 2 diabetes and its regulation by miRNAs.

Zhou X, Dai N, Yu D, Niu T, Wang S Front Med (Lausanne). 2024; 11:1443133.

PMID: 39144658 PMC: 11322075. DOI: 10.3389/fmed.2024.1443133.


Sleep fragmentation after traumatic brain injury impairs behavior and conveys long-lasting impacts on neuroinflammation.

Houle S, Tapp Z, Dobres S, Ahsan S, Reyes Y, Cotter C Brain Behav Immun Health. 2024; 38:100797.

PMID: 38803369 PMC: 11128763. DOI: 10.1016/j.bbih.2024.100797.